COMMUNIQUÉ DE PRESSE publié le 14/11/2024 à 22:05, il y a 1 année Monogram Technologies Reports Third Quarter 2024 Financial Results Monogram Technologies Inc. closed an oversubscribed $13 million public offering to fund near-term commercialization milestones. Submitted a 510(k) premarket filing, received an AIR from the FDA, and secured a strategic collaboration for clinical trials with Shalby Limited FDA Clinical Trials Public Offering Monogram Technologies Inc. 510(k) Filing
BRÈVE publiée le 16/10/2024 à 14:36, il y a 1 année 1 mois Monogram Technologies to Showcase Precision Robotics at LD Micro Main Event XVII Orthopedic Implants Monogram Technologies Robotic Surgery LD Micro Event AI And Robotics
BRÈVE publiée le 16/10/2024 à 14:36, il y a 1 année 1 mois Monogram Technologies présentera la robotique de précision lors du LD Micro Main Event XVII Technologies De Monogramme Implants Orthopédiques Chirurgie Robotique Micro-événement LD IA Et Robotique
COMMUNIQUÉ DE PRESSE publié le 16/10/2024 à 14:31, il y a 1 année 1 mois Monogram Technologies to Present at the LD Micro Main Event XVII Conference on Wednesday October 30, 2024 Monogram Technologies Inc., an AI-driven robotics company specializing in orthopedic surgery, to attend LD Micro Main Event XVII Conference at Luxe Sunset Blvd Hotel, LA, on October 29 - 30, 2024 Orthopedic Surgery AI-driven Robotics Monogram Technologies Inc. MBôs Precision Robotic Surgical System LD Micro Main Event XVII Conference
Publié le 04/12/2025 à 18:14, il y a 13 heures 33 minutes Résiliation d'une convention conclue entre actionnaires
Publié le 04/12/2025 à 18:00, il y a 13 heures 48 minutes Informations relatives au nombre total de droits de vote et d’actions composant le capital social au 28 novembre 2025
Publié le 04/12/2025 à 18:00, il y a 13 heures 48 minutes Information concerning the total number of voting rights and shares in the share capital as of November 28, 2025
Publié le 04/12/2025 à 17:45, il y a 14 heures 3 minutes Informations relatives au nombre total de droits de vote et d’actions
Publié le 04/12/2025 à 17:45, il y a 14 heures 3 minutes MONTHLY INFORMATION RELATING TO THE TOTAL NUMBER OF VOTING RIGHTS AND SHARES MAKING UP THE SHARE CAPITAL
Publié le 05/12/2025 à 02:35, il y a 5 heures 13 minutes Future Fuels Initates Drill Permitting at Hornby; Marketing Update
Publié le 05/12/2025 à 01:00, il y a 6 heures 48 minutes BEACN Closes First Tranche of Non-Brokered Private Placement
Publié le 04/12/2025 à 23:05, il y a 8 heures 43 minutes BlackBerry to Announce Third Quarter Fiscal Year 2026 Results on December 18, 2025
Publié le 04/12/2025 à 23:00, il y a 8 heures 48 minutes NXT Energy Solutions Completes Data Acquisition for SFD Survey
Publié le 05/12/2025 à 07:00, il y a 48 minutes Swiss Re targets a net income of USD 4.5 billion in 2026; refreshed strategy to strengthen core business
Publié le 05/12/2025 à 03:30, il y a 4 heures 17 minutes CGTN: What makes cooperation between China and France a two-way success
Publié le 04/12/2025 à 23:50, il y a 7 heures 57 minutes EQS-Adhoc: Dexus Finance Pty Limited: Dexus prices A$500 million of subordinated notes
Publié le 04/12/2025 à 20:25, il y a 11 heures 22 minutes Newmark Appoints Globally Recognized Real Estate Executive Peter Trollope to Lead Occupier Solutions
Publié le 04/12/2025 à 20:15, il y a 11 heures 33 minutes Galimedix Therapeutics presents compelling Phase 1 study results showing excellent safety and pharmacokinetics with oral small molecule GAL-101 at CTAD 2025